Global Alliance for TB Drug Development
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.tballiance.org
Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)
- Conditions
- Tuberculosis
- Interventions
- Drug: PA-824 200mgDrug: PA-824 50mg
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 32
- Registration Number
- NCT01830439
- Locations
- 🇺🇸
MDS Pharma Services (Celerion), Lincoln, Nebraska, United States
Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects
- Conditions
- Tuberculosis
- Interventions
- Drug: PA-824 1000 mg
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 16
- Registration Number
- NCT01828827
- Locations
- 🇺🇸
MDS Pharma Services, Lincoln, Nebraska, United States
Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 14
- Registration Number
- NCT01768273
- Locations
- 🇺🇸
MDS Pharma Services, Lincoln, Nebraska, United States
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 105
- Registration Number
- NCT01691534
- Locations
- 🇿🇦
Centre for Tuberculosis Research Innovation, UCT Lung Institute, Cape Town, South Africa
🇿🇦Task Applied Science, Karl Bremer Hospita, Cape Town, South Africa
Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 207
- Registration Number
- NCT01498419
- Locations
- 🇹🇿
Ifakara Health Institute, Bagamoyo, Tanzania
🇿🇦The Aurum Institute: Tembisa Hospital, Tembisa, South Africa
🇿🇦Klerksdorp Tshepong Hospital, Klerksdorp, South Africa
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 85
- Registration Number
- NCT01215851
- Locations
- 🇿🇦
Centre for Tuberculosis Research Innovation, UCT Lung Institute, Cape Town, South Africa
🇿🇦Task Applied Science, Karl Bremer Hospital, Cape Town, South Africa
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 68
- Registration Number
- NCT01215110
- Locations
- 🇿🇦
Karl Bremer Hospital, Belville, Cape Town, South Africa
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 69
- Registration Number
- NCT00944021
Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 1931
- Registration Number
- NCT00864383
- Locations
- 🇮🇳
Mahatma Gandhi Medical College& Hospital, Jaipur, Rajsthan, India
🇮🇳A-One Hospital, Delhi, India
🇮🇳Centre for advanced lung and sleep disorders, New Delhi, India
PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 69
- Registration Number
- NCT00567840
- Locations
- 🇿🇦
Tiervlei Trials Center, Stellenbosch University, Cape Town, Cape Province, South Africa
🇿🇦University of Cape Town Lung Institute, Cape Town, Cape Province, South Africa